ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 120,80
-0,94%
Dow Jones
42 801,72
0,52%
DAX
23 008,94
-1,87%
Brent Oil
70,235
0,00%
Bitcoin
84 376,84
-2,06%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) Actualités

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KZIA
DateHeureSourceTitreSymboleSociété
21/02/202512h33Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
20/02/202522h51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
20/02/202514h46PR Newswire (US)Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's DiseaseNASDAQ:KZIAKazia Therapeutics Ltd
06/02/202506h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
30/01/202522h31Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
30/01/202513h30PR Newswire (US)Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerNASDAQ:KZIAKazia Therapeutics Ltd
17/01/202522h30Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
16/01/202516h40Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
14/01/202522h00PR Newswire (US)Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
13/01/202514h00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
10/01/202515h58PR Newswire (US)Kazia Therapeutics Announces $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
31/12/202414h00PR Newswire (US)Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDANASDAQ:KZIAKazia Therapeutics Ltd
11/12/202414h00PR Newswire (US)Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
27/11/202422h30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:KZIAKazia Therapeutics Ltd
15/11/202422h02Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:KZIAKazia Therapeutics Ltd
14/11/202422h19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
07/11/202401h53Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
04/11/202413h30PR Newswire (US)Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma MultiformeNASDAQ:KZIAKazia Therapeutics Ltd
01/11/202421h05Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:KZIAKazia Therapeutics Ltd
24/10/202414h22Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
02/10/202414h45PR Newswire (US)Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society foNASDAQ:KZIAKazia Therapeutics Ltd
23/09/202414h30PR Newswire (US)Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
12/09/202413h30PR Newswire (US)KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERNASDAQ:KZIAKazia Therapeutics Ltd
10/07/202416h35AllPennyStocks.comBiotech Experiences Strong Open Following Major AnnouncementNASDAQ:KZIAKazia Therapeutics Ltd
10/07/202413h30PR Newswire (US)Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaNASDAQ:KZIAKazia Therapeutics Ltd
27/06/202414h15PR Newswire (US)KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERNASDAQ:KZIAKazia Therapeutics Ltd
23/05/202420h41PR Newswire (US)Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementNASDAQ:KZIAKazia Therapeutics Ltd
01/05/202414h45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
21/03/202413h52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
13/03/202413h00PR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:KZIA

Dernières Valeurs Consultées

BIT
UC3SBH
Unicredit Bank
BIT
RNG
Renergetica
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces